Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $97
Benzinga Newsdesk 18 hours ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $97.